Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda appears modest for now. We plan to promenade with the official mascot, catch up on our reading, and take a nap or three. And what about you? This is a fine time to keep warm in front of the telly or face time with friends. Or you could brave the temperatures and enjoy the great outdoors, perhaps frolic in the snow, if any landed your way. Well, whatever you do, have a grand time. But be safe, wear a mask. Enjoy, and see you soon. …

More than 65 institutional investors are urging the directors of companies making Covid-19 vaccines to tie executive compensation to vaccine equity in hopes of holding management “accountable” for contributing to a global health problem, STAT writes. In a series of letters, the investors asked the heads of the board compensation committees at Pfizer (PFE), Johnson & Johnson (JNJ), Moderna (MRNA), and AstraZeneca (AZN) to adopt goals outlined recently by the World Health Organization to ensure 70% of the global population is vaccinated by the end of 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment